Freespira s digital therapeutic for PTSD, panic disorder, panic attacks and other panic symptoms.
In addition to bringing the treatment to members living in Pennsylvania, Delaware and West Virginia, the agreement will also provide remote coaching on how to use Freespira to those not already receiving support from a behavioral health professional, according to the announcement. We are pleased with the clinical and financial outcomes achieved for our health plan members through the use of Freespira, Demetrios C. Marousis, director of behavioral health at Highmark, said in a statement. This breakthrough, drug-free treatment has reduced the impact of symptoms associated with panic attacks, resulting in reduced use of medications and other healthcare costs for symptom management. Freespira adds value to our members plans and helps us to create a remarkable health care experience, freeing people to be their best.
Share
23andMe s new COVID-19 resource. Consumer genomics company 23andMe has released a new interactive tool that allows users to see how various health factors could impact the risk of COVID-19 hospitalization. The COVID-19 Severity Calculator pulls data from the company s COVID-19 study, which included 10,000 participants diagnosed with the disease and 750 who were hospitalized.
23andMe warned that the tool shouldn t be used as a predictor for individual risk, and doesn t take lifestyle or certain underlying health conditions into account. However, it does identify certain characteristics that were frequently tied to severe symptoms and hospitalization, chief among which were obesity, Type 2 diabetes and lack of exercise.
William Carson says while the past year was full of challenges, embracing AI and other advanced technology led to impressive progress and opportunity.
When Saama Technologies appointed William Carson to its board of directors, they gained a seasoned industry professional with more than 20 years of experience under his belt. Currently chair of the board for Otsuka Pharmaceutical Development & Commercialization (OPDC), Carson has overseen R&D in a number of therapeutic areas, developed a track record of successful clinical development, and worked with global authorities on important regulatory matters.
Outsourcing-Pharma (OSP) recently connected with Carson (WC) to discuss the developments of 2020, what might lie ahead, and what industry professionals should know in order to succeed in the coming year.
Industry veteran: 2020 was the year our industry got it right outsourcing-pharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outsourcing-pharma.com Daily Mail and Mail on Sunday newspapers.